Home Primary Antibodies smooth muscle Myosin heavy chain 11 Antibody [J22F5]

research use only

smooth muscle Myosin heavy chain 11 Antibody [J22F5]

Catalog No.: F2948

    Application: Reactivity:

    Usage Information

    Dilution
    1:1000 - 1:10000
    1:1000
    1:50
    1:20
    Application
    WB, IHC, IF, FCM
    Reactivity
    Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    227 kDa 227 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.

    Datasheet & SDS

    Biological Description

    Specificity
    Smooth muscle Myosin heavy chain 11 Antibody [J22F5] detects endogenous levels of total smooth muscle Myosin heavy chain 11 protein.
    Clone
    J22F5
    Synonym(s)
    KIAA0866; MYH11; Myosin-11; Myosin heavy chain 11; SMMHC
    Background
    Smooth muscle myosin heavy chain 11 (MYH11) is a contractile protein belonging to the myosin II superfamily, forming the primary structural component of thick filaments in smooth muscle cells of blood vessels, gastrointestinal tract, and respiratory system. MYH11 consists of an N-terminal globular head domain containing actin-binding and ATPase sites, a neck region that pivots to amplify movement, and an extended α-helical coiled-coil tail domain that dimerizes with another heavy chain and associates with two pairs of regulatory light chains to form the functional hexameric myosin II molecule. MYH11 converts ATP hydrolysis energy into mechanical force by cyclically binding actin, undergoing a power stroke, and dissociating, enabling smooth muscle contraction regulated by RhoA/ROCK/MLC kinase signaling that phosphorylates myosin light chains to relieve inhibition. MYH11 maintains vascular tone, organ motility, and cytoskeletal integrity, interacting with tropomyosin and caldesmon to modulate actin-myosin dynamics during proliferation and migration. Mutations in MYH11 cause familial thoracic aortic aneurysm/dissection by disrupting contractile apparatus stability, while CBFB-MYH11 fusions characterize a favorable-risk acute myeloid leukemia subtype inv(16); additional associations include megacystis-microcolon-intestinal hypoperistalsis syndrome, patent ductus arteriosus, and visceral myopathies.
    References
    • https://pubmed.ncbi.nlm.nih.gov/22511748/
    • https://pubmed.ncbi.nlm.nih.gov/24711452/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.